raphe nuclei

**Anatomy** - Midline column of nuclei in the brainstem reticular formation, from the midbrain to the medulla. - Rostral group (midbrain/upper pons): dorsal raphe nucleus and median raphe nucleus. These project to the cortex, thalamus, hypothalamus, basal ganglia, hippocampus, and limbic structures. The dorsal raphe is the largest serotonergic nucleus and the key one for mood. - Caudal group (lower pons/medulla): raphe magnus, raphe pallidus, and raphe obscurus. These project down to the spinal cord, where the raphe magnus drives descending pain inhibition.

**Neurochemistry** - Neurotransmitter: serotonin (5-HT), made from tryptophan. Tryptophan is converted to 5-HTP by tryptophan hydroxylase (rate-limiting step), then to 5-HT by aromatic L-amino acid decarboxylase. - 5-HT is degraded by MAO to 5-HIAA, which is the urinary metabolite measured in carcinoid syndrome. - The pineal gland converts serotonin to melatonin. - The raphe nuclei hold most of the brain's serotonergic neurons. Their diffuse projections modulate nearly all CNS regions.

**Functions** - Mood and anxiety regulation. - Sleep-wake cycle: they are active in wakefulness, decrease firing in NREM sleep, and are nearly silent in REM sleep. They help regulate sleep architecture. - Descending analgesia: the periaqueductal gray (PAG) activates the raphe magnus, which sends serotonergic and enkephalinergic projections to dorsal horn interneurons. These inhibit ascending pain transmission. This is why opioids, SNRIs, and TCAs help in pain. - Appetite, thermoregulation, and GI motility (peripheral 5-HT comes mainly from enterochromaffin cells, not the raphe). - Respiratory and autonomic modulation. Medullary raphe serotonergic neurons contribute to CO2 chemosensitivity.

**Clinical correlations** - Depression, anxiety, and OCD: low serotonergic tone. SSRIs block SERT and increase synaptic 5-HT. Reduced raphe signaling is a key part of the monoamine hypothesis. - Serotonin syndrome: excess serotonergic activity from combining SSRIs, MAOIs, linezolid, meperidine, tramadol, triptans, MDMA, or St. John's wort. Features are hyperthermia, autonomic instability, clonus, hyperreflexia, and agitation. Treat with cyproheptadine (5-HT2A antagonist) plus supportive care. - Pain: loss of descending raphe-mediated inhibition may contribute to chronic pain. Duloxetine and TCAs are used for neuropathic pain and fibromyalgia. - Sleep: serotonin dysregulation is linked to insomnia. Raphe neurons also take part in REM-on/REM-off circuitry. - SIDS: some studies found abnormal serotonergic raphe/medullary function in infants who died of SIDS, and this is an active research area. - Sudden unexpected death in epilepsy (SUDEP) and seizure-related respiratory arrest: impaired serotonergic raphe signaling may reduce CO2 chemosensitivity. - Autoreceptors: 5-HT1A autoreceptors on raphe cell bodies provide negative feedback. This is why SSRIs take weeks to work, because the autoreceptors must desensitize. Buspirone is a 5-HT1A partial agonist used for anxiety. - Pharmacology: SSRIs, SNRIs, TCAs, MAOIs, and buspirone act on this system. Triptans (5-HT1B/1D agonists) and ondansetron (5-HT3 antagonist) act on other serotonin receptors.

**High-yield pearls** - Raphe nuclei are the main serotonin source, locus coeruleus is the main norepinephrine source, and the VTA/substantia nigra supply dopamine. - The nucleus basalis of Meynert supplies acetylcholine (lost in Alzheimer disease). - Raphe magnus is the descending pain-control nucleus, and the PAG sits above it in the pathway. - Neuron loss in the dorsal raphe is seen in Parkinson disease and Alzheimer disease, which may contribute to the depression common in these conditions.